NeurologyLive® Friday 5 — January 26, 2024

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 26, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: CMSC Consensus Panel Guidance: Challenges and Opportunity With MRI

In episode 4 of the "CMSC Consensus Panel Guidance on the Use of Serum Neurofilament Light Chain in the Management of Multiple Sclerosis" video series, Ahmed Obeidat, MD, PhD, assistant professor of neurology at The Medical College of Wisconsin, recounts the difficulties with MRI as a main biomarker for MS and shares strategies for optimal use of the technology.

Challenges and Opportunity With MRI

2: The Future of Chronic Inflammatory Demyelinating Polyneuropathy Treatment With the FDA Approval of Hyqvia: Richard Lewis, MD

Richard Lewis, MD, director of the electromyography laboratory and professor of neurology at Cedars-Sinai Medical Center, shared his clinical perspective on the recent FDA approval of Takeda’s immune globulin infusion, Hyqvia, for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 5 minutes]

The Future of Chronic Inflammatory Demyelinating Polyneuropathy Treatment With the FDA Approval of Hyqvia: Richard Lewis, MD

3: 2024 Clinical Preview for Epilepsy and Seizure Disorders: Claude Steriade, MD, CM

Claude Steriade, MD, CM, an epileptologist at NYU Langone Health and associate professor of neurology at the NYU Grossman School of Medicine, shared her thoughts on potential therapies and expanding management care options for patients with epilepsy in the near future. [WATCH TIME: 5 minutes]

2024 Clinical Preview for Epilepsy and Seizure Disorders: Claude Steriade, MD, CM

4: NeuroVoices: Stephen From, on AB126 and Exosomes in Treating Stroke

In this week's NeuroVoices Q&A, Stephen From, chief executive officer of Aruna Bio, provided context on a newly accepted phase 1/2 trial assessing the company’s neural-derived exosome agent AB126 in patients with acute ischemic stroke.

NeuroVoices: Stephen From, on AB126 and Exosomes in Treating Stroke

5: Finding Positivity Through Adversity in Poststroke Care: Harmony Sierens, MD

Harmony Sierens, MD, a physiatrist and medical director of the Inpatient Rehabilitation Unit at Ascension Genesys Hospital, discussed the importance of early intervention, sustained care, and rehabilitation in managing poststroke patients. [WATCH TIME: 4 minutes]

Finding Positivity Through Adversity in Poststroke Care: Harmony Sierens, MD
Related Videos
 Bruce Cree, MD, PhD, MAS, FAAN
Video 3 - 5 KOLs are featured in "Transitions of Care: Moving Spinal Muscular Atrophy Patients from Pediatric/Adolescent Care to Adult Clinics"
Video 3 - 5 KOLs are featured in "Presentation of Adult Spinal Muscular Atrophy in Clinics"
Fawad Khan, MD, FACNS
Valerie J. Block, PT, DPTSc
Sanjay R. Patel, MD, MS
© 2024 MJH Life Sciences

All rights reserved.